Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis

被引:17
作者
Kim, Se-Chan [1 ]
Tran, Nicole [1 ]
Schewe, Jens-Christian [1 ]
Boehm, Olaf [1 ]
Wittmann, Maria [1 ]
Graeff, Ingo [1 ]
Hoeft, Andreas [1 ]
Baumgarten, Georg [1 ]
机构
[1] Univ Hosp, Dept Anesthesiol & Intens Care Med, D-53127 Bonn, Germany
来源
JOURNAL OF CARDIOTHORACIC SURGERY | 2015年 / 10卷
关键词
Argatroban; Heparin induced thrombocytopenia; Critical care; HEPARIN-INDUCED THROMBOCYTOPENIA; RISK-FACTORS; ICU PATIENTS; SAPS-II; ANTICOAGULATION; THROMBOSIS; DIAGNOSIS; THERAPY; CARE; OVERDIAGNOSIS;
D O I
10.1186/s13019-015-0214-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Heparin-induced thrombocytopenia (HIT) causes thromboembolic complications which threaten life and limb. Heparin is administered to virtually every critically ill patient as a protective measure against thromboembolism. Argatroban is a promising alternative anticoagulant agent. However, a safe dose which still provides effective thromboembolic prophylaxis without major bleeding still needs to be identified. Methods: Critically ill patients (n = 42) diagnosed with HIT at a tertiary medical center intensive care unit from 2005 to 2010 were included in this retrospective analysis. Patient records were perused for preexisting history of HIT, heparin dosage before HIT, argatroban dosage, number of transfusions required, thromboembolic complications and length of ICU stay (ICU LOS). Patients were allocated to Simplified Acute Physiology Scores above and below 30 (SAPS > 30, SAPS < 30), respectively. For calculations, patients (n = 19) without previous history of HIT were compared to patients (n = 23) with a history of HIT before initiation of argatroban. Results: The mean initial argatroban dosage was below 0.4 mcg/kg/min regardless of SAPS score. Maintenance dosage had to be increased in patients with SAPS < 30 to 0.54 +/- 0.248 mcg/kg/min (p >0.05) to achieve effective anticoagulation. No thromboembolic complications were encountered. Argatroban had to be discontinued temporarily in 16 patients for a total of 57 times due to diagnostic or surgical procedures, supratherapeutic aPTT and bleeding without increasing the number of transfusions. A history of HIT was associated with a shorter ICU LOS and significantly reduced transfusion need when compared to patients with no history of HIT. Cost calculation favour argatroban due to increased transfusion needs during heparin administration and increase ICU LOS. Conclusion: Argatroban can be used at doses < 0.4 mcg/kg/min without an increase in transfusion requirements and at a reduced overall treatment cost compared to heparin.
引用
收藏
页数:8
相关论文
共 33 条
  • [1] Argatroban anticoagulation in critically ill patients
    Beiderlinden, Martin
    Treschan, Tanja A.
    Goerlinger, Klaus
    Peters, Juergen
    [J]. ANNALS OF PHARMACOTHERAPY, 2007, 41 (05) : 749 - 754
  • [2] Overdiagnosis of Heparin-Induced Thrombocytopenia in Surgical ICU Patients
    Berry, Cherisse
    Tcherniantchouk, Oxana
    Ley, Eric J.
    Salim, Ali
    Mirocha, James
    Martin-Stone, Sylvia
    Stolpner, Dennis
    Margulies, Daniel R.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2011, 213 (01) : 10 - 17
  • [3] Severe heparin-induced thrombocytopenia: When the obvious is not obvious, a case report
    Cormack G.M.
    Kaufman L.J.
    [J]. Journal of Medical Case Reports, 1 (1)
  • [4] Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis
    Cuker, Adam
    Gimotty, Phyllis A.
    Crowther, Mark A.
    Warkentin, Theodore E.
    [J]. BLOOD, 2012, 120 (20) : 4160 - 4167
  • [5] Heparin-induced thrombocytopenia (HIT) in 2011: An epidemic of overdiagnosis
    Cuker, Adam
    [J]. THROMBOSIS AND HAEMOSTASIS, 2011, 106 (06) : 993 - 994
  • [6] Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery
    De, Anushtup
    Roy, Prabal
    Garg, Vinod K.
    Pandey, Narendra K.
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2010, 21 (01) : 57 - 61
  • [7] Bleeding risk factors associated with argatroban therapy in the critically ill
    Doepker, Bruce
    Mount, Kari L.
    Ryder, Lindsay J.
    Gerlach, Anthony T.
    Murphy, Claire V.
    Philips, Gary S.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2012, 34 (04) : 491 - 498
  • [8] An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time
    Engstrom, M.
    Rundgren, M.
    Schott, U.
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2010, 54 (01) : 86 - 91
  • [9] Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia
    Fabris, F
    Luzzatto, G
    Soini, B
    Ramon, R
    Scandellari, R
    Randi, ML
    Girolami, A
    [J]. JOURNAL OF INTERNAL MEDICINE, 2002, 252 (02) : 149 - 154
  • [10] Fabris F, 2000, HAEMATOLOGICA, V85, P72